Evidence map›Paper›PMID 41599296›Full record

ReviewMolecules (Basel, Switzerland)2026

Anticancer Potential of Atractylenolides I-III: Efficacy, Mechanisms, Pharmacokinetics, and Safety.

Lujia Zhang, Jinjian Lu, Mengning Zhang, Yingying Dong, Yutao Luo, Tiantian Lei, Zhujun Bian, Xiaofeng Yuan, Hong Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lujia ZhangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Jinjian LuState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China.ORCID 0000-0001-6703-3120
Mengning ZhangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yingying DongThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Yutao LuoThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Tiantian LeiThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Zhujun BianThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.
Xiaofeng YuanSchool of Life Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID 0000-0002-9048-1754
Hong ZhaoThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.ORCID 0000-0002-7187-2514

Funding

the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2022KY232
6 · The paper itself

Abstract

Atractylenolides (ATs; mainly AT-I, II, and III), as one of the primary active components of the traditional Chinese medicine

Indexed as

Antineoplastic AgentsLactonesNeoplasmsSesquiterpenesAnimalsApoptosisAtractylodesHumansAntineoplastic Agentsatractylenolide Iatractylenolide IIILactonesSesquiterpenesatractylenolides (I, II, and III)cancerefficacymechanismpharmacokineticssafety

Identifiers

PMID41599296
PMCPMC12844320

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.